Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:11 PM
Ignite Modification Date:
2025-12-24 @ 7:11 PM
NCT ID:
NCT00329303
Eligibility Criteria:
Inclusion Criteria:
* Subject having responded to treatment at Week 12 in study C87040 and having relapsed during the follow-up period
* Female subjects either postmenopausal for at least one year, surgically incapable of childbearing, or effectively practising an acceptable method of contraception.Subjects agreed to continue using adequate contraception during the study and for 12 weeks after the last dose of CDP870
Exclusion Criteria:
* Subjects with erythrodermic, guttate, generalized pustular form of psoriasis
* Any recent serious or life-threatening infection or any current sign or symptom that may indicate an infection (e.g., fever, cough)
* Positive hepatitis B surface antigen test and /or hepatitis C antibody test results
* Positive human immunodeficiency virus (HIV) test result
* White blood cell counts less than 4000 per cubic millimeter or more than 20000 per cubic millimeter
* Suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis)
* Systemic Lupus Erythematosus
* Participation in a clinical study within the past 3 months except Study C87040
* Any other condition, which in the Investigator's judgment would make the subject unsuitable for inclusion in the study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00329303
Study Brief:
Protocol Section:
NCT00329303